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Abstract: Art v 1 is the major allergen of mugwort (Artemisia vulgaris) pollen, 
a significant cause of hay fever all over Europe. Specific immunotherapy is the 
only treatment modality for allergic disease. Application of modified allergens 
makes the treatment safer and more efficient. In this work, two out of three (ci-
traconic anhydride, cis-aconitic anhydride, 2,3-dimethylmaleic anhydride) test-
ed anhydrides were proven to be suitable for chemical modifications of aller-
gens. Art v 1 was modified by cis-aconitylation and citraconylation in order to 
obtain derivatives of Art v 1 that may be suitable for further immunological test-
ing. Acylation of Art v 1 gave derivatives (caaArt v 1 and citArt v 1) with about 
80 % modified amino groups. The derivatives were in the monomeric form and 
had dramatically reduced pI values. Both derivatives were relatively stable at 
neutral pH values, while the acyl groups undergo hydrolysis under acidic con-
ditions. Modification of allergens by cis-aconitylation and citraconylation could 
be a new tool for obtaining allergoids. 
Keywords: allergoid; mugwort pollen; Art v 1; chemical modification; allergen-
-specific immunotherapy. 
INTRODUCTION 
IgE-mediated allergy is a global problem affecting more then 40 % of the 
population in industrialized countries.1 In contrast to symptomatic treatments, 
specific immunotherapy (SIT) is the only prophylactic desensitizing therapy for 
allergy.2,3 SIT modifies cellular and humoral responses to allergens by driving 
the immune response from the T helper 2 (Th 2) towards the T helper 1 (Th 1) 
type and generating allergen-specific regulatory T cells that can suppress the 
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responses of effector T cells, accompanied with an increase in allergen-specific 
antibodies of the IgG class (blocking antibodies).4 On the other hand, the poten-
tial for local and systemic reactions has forced improvements to the traditional 
use of allergen extracts. The main approaches involve the generation of hypoal-
lergenic derivatives, by chemical modification5,6 or protein engineering of re-
combinant allergens,7,8 which are aimed at reducing potentially fatal reactions to 
allergen administration during immunotherapy. On the other hand, altered aller-
gens have to retain their immunogenicity, i.e., recognition of the modified aller-
gen by T cells.
 Finally, it would be useful to have immunogens with an inherent 
strong Th 1-skewing potential, which is usually obtained by the usage of an adju-
vant (e.g., a monophosphoryl lipid).9 
Scavenger receptors (SR) expressed on antigen presenting cells (APC) bind a 
variety of polyanionic ligands, thus delivering them into the endolysosomal path-
way.10 Many proteins are known to become SR ligands when chemically modi-
fied to enhance their negative charge by alteration of the ε-amino groups of their 
lysine residues with acetic or maleic anhydride.11 It was shown that maleylating 
protein immunogens, so that they become SR ligands, leads to a more efficient 
antigen presentation to T cell receptors and to a greater immunogenicity with a 
dominantly Th 1 type of immune response.12,13 The main problem with usage of 
modified immunogens is a reduced immunogenicity as consequence of affinity 
loss of T cell receptors for the modified epitopes. Shakushiro et al.14 showed that 
ovalbumin (OVA) modified to become more acidic by succinylation (Suc-OVA), 
maleylation (Mal-OVA) or cis-aconitylation (Aco-OVA) was efficiently taken up 
by dendritic cells (DC) via SR. Mal-OVA and Aco-OVA were efficiently cross- 
-presented by DC, while cross-presentation of Suc-OVA was hardly observed. In 
contrast to Mal-OVA and Aco-OVA, which are prone to deacylatation in lisoso-
mes, Suc-OVA is chemically stable under acidic conditions. As a consequence, 
succinyl groups inhibit ubiquitin conjugation on the lysine residues, which is 
important in proteasomal degradation,15 leading to the lack of recognition by T 
cells through T cell receptors (TCR). 
Although a clear reduction in immunogenicity was observed for many aller-
goids,5,6 hitherto the approach of reversible modification of allergens with the 
aim of preserving immunogenicity and recognition of T-cell receptors has not 
been reported. 
Mugwort (Artemisia vulgaris) pollen is an important cause of allergy in Eu-
rope. Ninety-five percent of patients with mugwort allergy are sensitized to Art v 
1, the sole major allergen in mugwort pollen.16,17 
The aim of this work was to modify chemically Art v 1 with new modifying 
agents with specific features, i.e., the introduction of highly negative charges that 
may enable them to react with scavenger receptors on antigen presenting cells 
and their reversible modification that may improve their immunogenicity when 
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compared to the traditionally used chemically modified allergens. In this study, 
three new chemical agents were tested and the obtained allergoids were bioche-
mically characterized. Purified Art v 1 was modified by citraconic, cis-aconitic 
and 2,3-dimethylmaleic anhydride. cis-Aconitylation and citraconylation of Art v 
1 gave derivatives (caaArt v 1 and citArt v 1), with about 80 % modified amino 
groups and dramatically reduced pI values, which could make them good can-
didate allergoids. The stability of the bond formed enables further animal testing 
of these derivatives. 
EXPERIMENTAL 
Citraconic anhydride, cis-aconitic anhydride, 2,3-dimethylmaleic anhydride and 2,4,6-tri-
nitrobenzensulfonic acid (TNBS) were purchased from Sigma-Aldrich (Steinheim, Germany). 
All other chemicals used in this work were of analytical grade. 
Acylation of Art v 1 
Art v 1 was isolated from pollen extract of Artemisia vulgaris and purified by ion-ex-
change HPLC.18 Art v 1 (1.5 mg/ml) in 4 % NaHCO3 was treated with the bolus addition of 
15 portions of cis-aconitic or dimethylmaleic or citraconic anhydride during 30 min with ex-
tensive mixing at 4 °C. The final anhydride concentration was 400 mM. After every bolus ad-
dition, the pH was adjusted to 9.0 with solid Na2CO3. The mixture was extensively dialyzed 
against phosphate buffered saline (PBS) for 20 h at 4 °C. All samples were stored at –20 °C 
until use. 
Determination of the free amino groups 
The free amino groups were determined using the TNBS method.19 The results are ex-
pressed as the means of three different determinations for modified Art v 1 as a percentage of 
the number of amino groups determined for the native Art v 1 (expressed as 100 %). 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE), native PAGE and 
isoelectric focusing (IEF) 
Native and modified Art v 1 were analyzed by SDS PAGE (12 % polyacrylamide gels) 
under reducing condition using the Laemmli method.20 Molecular weight standards were run 
simultaneously. Native PAGE was realized as for the SDS PAGE but under native conditions, 
without the addition of SDS in the sample buffer and in the electrophoresis buffer. The protein 
bands were stained with Coomassie Brilliant Blue R-250. 
High-performance gel filtration liquid chromatography (HPLC) 
Size exclusion HPLC was performed using an Akta HPLC system equipped with a Su-
perdex 75 PC 3.2/30 (3.2 mm×300 mm) column (Amersham Pharmacia Biotech, Sweden). 
Before analysis, the samples were centrifuged (20 min, 12000 g) and 10 μl of the supernatant 
was injected onto the column. The components were eluted with 50 mM Tris buffer pH 8.2 
containing 0.2 M NaCl and 1 mM EDTA at a flow rate of 0.05 ml/min and detected at 215 
and 280 nm. 
Protein concentration determination 
The protein concentrations of the native and modified proteins were determined spectro-
photometrically at 280 nm using an extinction coefficient 640 ml mg-1 cm-1, calculated for Art 
v 1 as described previously.18 
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pH stability 
The pH stability of the Art v 1 derivatives was estimated by determination of the free 
amino groups remaining after exposure of the derivatives to PBS (pH 7.2), 100 mM acetate 
buffer (pH 4.5) or 100 mM phosphate buffer (pH 2.0) at 37 °C for 1, 4 and 18 h. The results 
are expressed as means of two different determinations for modified Art v 1 as a percentage of 
the number of amino groups determined for the native Art v1 (expressed as 100 %). 
RESULTS AND DISCUSSION 
In present study, Art v 1 was modified by adding negative charges, which 
should, in principle, facilitate SR-mediated uptake and presentation of this aller-
gen by APC and increase its immunogenicity. After treatment of Art v 1 with cis-
-aconitic and citraconic anhydrides, Art v 1 derivatives, caaArt v 1 and citArt v1, 
respectively, were obtained with 80 % of the amino groups modified. In the 2,3-di-
methylmaleic anhydride-treated Art v 1, number of amino groups was similar to 
that in unmodified Art v 1 (Table I). As dimethylmaleyl groups easily hydrolyze 
at neutral pH,21 it is supposed that Art v 1 was actually modified with 2,3-dime-
thylmaleic anhydride but that this derivative (dmaArt v 1) was hydrolyzed during 
the 20 h dialysis against PBS. All derivatives were completely soluble over a 
wide range of pH values (2.0–10). 
TABLE I. Percent of remaining amino groups after Art v 1 treatment with citraconic, cis-aco-
nitic and 2,3-dimethylmaleic anhydride, estimated by the TNBS method 
Derivative Amino  groups,  % 
Art v 1  100±2.7 
citArt v 1  23.1±1.8 
caaArt v 1   22.2±1.5 
dmaArt v 1  96.6±3.8 
SDS PAGE demonstrated that caaArt v 1 and citArt v 1 were monomers with 
molar masses virtually indiscernible from that of unmodified Art v 1 (Fig. 1a). 
The size exclusion chromatograms (Fig. 2) show that, according to the retention 
times of the derivatives, citArt v 1 (tr = 22.35 min) and caaArt v 1 (tr = 21.83 min) 
had slightly increased molecular masses compared to unmodified Art v 1 (tr = = 
23.69 min). Retention of the monomeric structure, with molar masses similar to 
that of native Art v 1, as well as their complete solubility, makes these derivati-
ves promising candidates as immunogens for allergen immunotherapy. 
The native PAGE results show that the derivatives were very acidic in con-
trast to native Art v 1 (pI around 8), which did not even enter into the running gel 
(Fig 1b). caaArt v 1 was more acidic than cit Art v 1 because it has one carboxyl 
group more per introduced acyl group. By IEF, it was observed that the pI value 
of the derivatives was lower then 3.5 (results not shown). These results suggest 
that these derivatives with a very high negative charge density could be good SR 
ligands. Also with a so significantly altered structure, it is expected that the IgE 
binding would be dramatically reduced. 
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(a)  (b) 
Fig. 1. a) SDS PAGE of unmodified Art v 1 (lane 1), caaArt v 1 (lane 2) and citArt v 1 
(lane3); b) native PAGE. 
       
  Panel A  Panel B  Panel C 
Fig. 2. Size exclusion chromatograms of native Art v 1 (panel A), 
citArt v 1 (panel B) and caaArt v 1 (panel C). 
The pH stability test of the Art v 1 modifications showed that at physiolo-
gical pH (pH 7.4), the half life is 30 and 25 h for caaArt v 1 and citArt v 1, res-
pectively. At pH 4.5 (pH in the lysosomal compartment), the half-life of caaArt v 
1 and citArt v 1 was 6 and 2 h, respectively. Finally, at pH 2.0, the half-life of 
both derivatives was about 2 h (Fig. 3). The stability of the derivatives at pH 7.0 
should enable their relatively long half-life in circulation. On the other hand, their 
short half-life in an acidic environment, such as lysosomes during antigen proces-
sing, should enable these modified allergens to retain immunogenicity, i.e. to sti-
mulate allergen specific T cells in a similar manner to native allergens. 
In order for a protein to act as a good SR-ligand, it must have a certain ne-
gative charge density. On the other hand, a too high level of acetylation or succi-
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nylation (which could provide this property) might decrease immunogenicity and 
T cell recognition. In contrast, a high degree citraconylation and cis-aconitylation 
generates two and three times greater negative charge density compared to ace-
tylation (and, consequently, giving much better ligands for SR). A further poten-
tial advantage of the studied chemical modifications is the expected hydrolysis of 
acyl groups during antigen processing, which should allow the generation by an 
APC of the same set of peptides as the native allergen. This could be especially 
important because it was shown that T cell response to Art v 1 is characterized by 
one strong immunodominant epitope of 15 amino acids, containing up to three 
lysine residues.22 
 
(a) 
 
(b) 
Fig. 3. pH stability of a) citArt v 1 
and b) caaArt v 1. The results are 
presented as percent of the remain-
ing amino groups of the modified 
Art v 1, taking the number of native 
Art v 1 amino groups as 100 %. 
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CONCLUSIONS 
In this work, the preparation of reversibly modified Art v 1, the major mug-
wort allergen, by treatment with citraconic, cis-aconitic anhydride and 2,3-dime-
thylmaleic anhydridesis described. Acylation of Art v 1 by treatment with citra-
conic and cis-aconitic anhydride gave highly negatively charged derivatives (caaArt 
v 1 and citArt v 1). As 2,3-dimethylmaleyl derivative was hydrolyzed rapidly even 
at neutral pH values, this derivative was too unstable to be studied further and 
thereby was dismissed as a potential allergoid candidate. Additionally, the low 
stability of caaArt v 1 and citArt v 1 in an acidic environment would enable the 
complete retention of the specificity of the unmodified allergen. Modification of 
allergens by cis-aconitylation and citraconylation could be a new strategy for 
safer and more efficient allergen-specific immunotherapy. The derivatives ob-
tained by citraconic and cis-aconitic anhydride treatment are suitable for further 
immunological testing. 
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ИЗВОД 
ХЕМИЈСКЕ МОДИФИКАЦИЈЕ Art v 1, ГЛАВНОГ АЛЕРГЕНА Artemisia vulgaris, 
cis-АКОНИТИЛОВАЊЕМ И ЦИТРАКОНИЛОВАЊЕМ 
ДРАГАНА СТАНИЋ1, ЛИДИЈА БУРАЗЕР2, МАРИЈА ГАВРОВИЋ-ЈАНКУЛОВИЋ3, 
РАТКО M. ЈАНКОВ3 и ТАЊА ЋИРКОВИЋ ВЕЛИЧКОВИЋ3 
1Institut za hemiju, tehnologiju i metalurgiju – Centar za hemiju, Wego{eva 12, 11001 Beograd, 
2Institut za virologiju, vakcine i serume – Torlak, Vojvode Stepe 458, 11221 Beograd i 
3Hemijski fakultet, Univerzitet u Beogradu, Studentski trg 16, 11001 Beograd 
Art v1 је главни алерген полена црног пелина (Artemisia vulgaris), значајног узрочника 
поленске грознице широм Европе. Алерген-специфична имунотерапија је за садa једини де-
лотворан начин за третирање алергија, при чему примена модификованих алергена чини ова-
кав третман безбеднијим и ефикаснијим. У овом раду, два од три (анхидрид cis-аконитне, 
цитраконске и 2,3-диметилмалеинске киселине) испитивана анхидрида су се показала погод-
ним за хемијске модификације алергена. Art v 1 је модификован cis-аконитиловањем и цит-
ракониловањем у циљу добијања деривата Аrt v 1 погодних за даље имунолошке тестове. 
Ациловањем Art v 1 добијени су деривати (caaArt v 1 и citАrt v 1) са око 80 % измодифико-
ваних амино група. Добијени деривати су мономерни, са молекулском масом сличном натив-
ном Art v 1, али са драматично смањеним pI вредностима. Оба деривата су релативно ста-
билна у неутралној, док се у киселој средини ацил групе хидролизују. Mодификација алер-
гена cis-аконитиловањем и цитракониловањем може бити нови начин за добијање алергоида. 
(Примљено 19. септембра, ревидирано 6. новембра 2008) 
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